Skip to main content
Equibles
COAG logo

COAG · Hemab Therapeutics Holdings, Inc.

Track COAG — free

Use COAG with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research COAG.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$31.11 +0.05 (+0.16%) At close · Oct 2
Russell 2000 member Rebalance outlook locked
Market Cap
$1.52B
Shares
46.71M
Volume · Oct 2 354.15K Avg daily vol (3M) 454.32K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$31.11 Open$31.49 Day$30.06–31.49 Available close range$24.98–54.94 Avg vol 30d539K Short int2.6M · 5.7% float · 7.5d Short vol83% Last earningsAug 11, 2026 DataMay 2026–Oct 2026 Filing10-Q · Aug 11

The closing range uses available history since May 1, 2026; less than a full year is stored.

Up next

Latest filing: 10-Q
filed Aug 11, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$457.46M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+3,083.0%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
5.7%
Latest settlement · 7.5 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Limited Sentiment Neutral Fundamentals Limited Quant / Vol Very High
Market backdrop VIX 15.3 · calm Equity put/call 0.58
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 50-day avg −30%
below
RSI (14) 23
oversold
MACD trend Negative
52-week position 20%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Limited
Not enough data for a confident read.
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Accumulating
+56 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
5.65% of float · ▲ +25.3% MoM · 7.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
56 holders — 13F breadth
Squeeze score 71
high risk · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Very High
Volatility 90%
annualized · 1-yr
Max drawdown −44%
past year
ATR 9.2%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
2 · 4 · 0
50 / 200-day cross
No cross Neutral
Price vs 50-day avg
−30% Bearish
RSI (14)
23 Neutral
MACD trend
Negative Bearish
52-week position
20% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Accumulating
+56 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
5.65% of float · ▲ +25.3% MoM · 7.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
56 holders — 13F breadth
Price context
position in its available closing range
Range low $25 Now $31 · 20% Range high $55
vs 50-day avg -30%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
COAG
Hemab Therapeutics Holdings, Inc.
this stock
$1.52B — — — 5.7%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $133.37B +11.3% +46.2% 30.7 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
 $81.13B -4.8% +20.8% 19.5 2.5%
MRNA
Moderna, Inc.
 $79.40B +544.3% +4.3% — 8.2%
CSLLY
Csl Ltd
 $61.25B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
56
% held
77.6%
Net QoQ
+36.3M sh
Top holder
RA CAPITAL MANAGEMENT, L.…
Held Float
View
Held by Funds
Fund positions
60
View
Short & Settlement
Short Interest Rising
Shares short
2.6M
Days to cover
7.5d
Change
+533.0K sh
View
Short Volume
Short vol %
83%
As of
Oct 2, 2026
Short Total
View
Fails to Deliver
FTD shares
1.4K
Value
$60.9K
As of
Sep 9, 2026
View
Off-Exchange
Off-exchange %
47.6%
Week of
Aug 31, 2026
Off-exch Lit
View
Filings
SEC Filings
Latest
8-K
Filed
Sep 24, 2026
This year
8
View
Earnings & Events
Webcasts
Last webcast
Aug 11, 2026
View

Performance

5D 20D 120D MTD YTD
COAG -10.5% -29.9% — +0.9% —
SPY -0.2% -0.5% +12.2% +0.9% +12.9%
vs SPY -10.2% -29.4% — 0.0% —
Key facts CIK 2114044 CUSIP 423494103 13F (30d) 2 filings 2 filers Visit website Investor relations